June 2015

 

In this Supplement

Complete Coverage for Complex In-Stent Restenosis

Data, comparative analysis, and consensus on the role of the GORE® VIABAHN® Endoprosthesis.

Issue

Supplement

Supplement

Download a PDF of this supplement

COMPLETE COVERAGE FOR COMPLEX IN-STENT RESTENOSIS

Data-Driven Treatment Approach to In-Stent Restenosis

By George L. Adams, MD, MHS, FACC, FSCAI; Robert M. Bersin, MD, FACC, FSCAI; Jon C. George, MD, FACC, FSCAI; Vinayak Subramanian, BS; Peter A. Soukas, MD, FACC, FSVM, FSCAI, FACP, RPVI

CASE REPORT

The GORE® VIABAHN® Endoprosthesis for In-Stent Restenosis in the Superficial Femoral Artery

By Robert L. Minor, Jr, MD, and Jeffrey R. Cook, MD

CASE REPORT

The GORE® VIABAHN® Endoprosthesis for Recurrent In-Stent Restenosis

By Peter A. Soukas, MD, FACC, FSVM, FSCAI, FACP, RPVI

CASE REPORT

Treating ISR With the GORE® VIABAHN® Endoprosthesis After Bilateral SFA CTO Interventions

By Robert M. Bersin, MD, FACC, FSCAI

Innovation Fueling Evolution: Two Decades of the GORE® VIABAHN® Endoprosthesis

Through the incorporation of technological advances, the contemporary GORE VIABAHN Device has evolved to offer robust treatment options to a diverse and growing population of patients with peripheral artery disease.

By M. Casey Becker, MD, FACC, FSCAI, FSVM

Optimal Technique for Use of the GORE® VIABAHN® Endoprosthesis

Best practices and treatment considerations for using stent-grafts.

By Barry S. Weinstock, MD, FACC
 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.